Publication date: 17 November 2026 Source: Cell Reports Medicine, Volume 7, Issue 11 Author(s): Angela L. Rachubinski, Emily Gurnee, Elizabeth B. Wallace, Belinda A. Enriquez Estrada, Kayleigh R. Worek, Rachel M. Shropshire, Bellina P. Guerra, Sitlali Flores Garcia, Pamela Navarette, Keith P. Smith, Ross E. Granrath, Brian F. Niemeyer, Eleanor C. Britton, Hannah R. Lyford, Madelaine Hipp, Ashley Snell, Neetha P. Eduthan, Micah G. Donovan, Kaylyn Van Deusen, Linda K. Roan
A phase 2, open-label, single-arm clinical trial of the safety and efficacy of the JAK1/3 inhibitor tofacitinib in Down syndrome. // Chinese General Practice Journal. – URL: https://www.sciencedirect.com/science/article/pii/S2666379126005550?dgcid=rss_sd_all
A phase 2, open-label, single-arm clinical trial of the safety and efficacy of the JAK1/3 inhibitor tofacitinib in Down syndrome. Chinese General Practice Journal. https://www.sciencedirect.com/science/article/pii/S2666379126005550?dgcid=rss_sd_all
“A phase 2, open-label, single-arm clinical trial of the safety and efficacy of the JAK1/3 inhibitor tofacitinib in Down syndrome.” Chinese General Practice Journal.
@article{article4630,
title = {A phase 2, open-label, single-arm clinical trial of the safety and efficacy of the JAK1/3 inhibitor tofacitinib in Down syndrome},
journal = {Chinese General Practice Journal},
url = {https://www.sciencedirect.com/science/article/pii/S2666379126005550?dgcid=rss_sd_all}
}
Publication date: December 2026 Source: Journal of Electromyography and Kinesiology, Volume 91 Author(s): Pierre Garnault, Yannick Aoustin, Vigen Arakelian
Publication date: December 2026 Source: Journal of Electromyography and Kinesiology, Volume 91 Author(s): Mihailo Petrovic, Ann-Katrin Stensdotter, Helena Grip
Publication date: December 2026 Source: Journal of Electromyography and Kinesiology, Volume 91 Author(s): Michael Croskery, Victor Chan, Ryan B. Graham